Published by Coherent Market Insights
Posted on September 27, 2021
4 min readLast updated: February 2, 2026
The Glioblastoma Multiforme Treatment market is expanding due to rising brain tumor cases and new drug approvals, with North America leading.
“The Recurrent Glioblastoma Multiforme Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/682
The growing incidence of brain tumors is projected to foster the growth of the global glioblastoma multiforme market during the forecast period. As per the National Foundation for Cancer Research, GBM is the deadliest type of brain cancer, accounting for 45% of all malignant brain tumors. Furthermore, according to the article published by the National Brain Tumor Society, over 10% of people with brain tumors are at high risk of developing glioblastomas. Additionally, key players in the market are involved in joint ventures and partnerships to develop and commercialize novel drugs, in order to strengthen their business in the global glioblastoma multiforme market. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences to conduct phase 3 trials of VAL-083 for the treatment of recurrent GBM.
North America is expected to dominate the global glioblastoma multiforme market and this is attributed to the increasing drug approvals and launches for GBM treatment is again expected to boost the growth of the global glioblastoma multiforme treatment market. For instance, in January 2020, Pfizer launched ‘Zirabev’ in the U.S., which is a bevacizumab biosimilar of Avastin, approved for the treatment of recurrent glioblastoma multiforme. The biosimilar was approved by FDA in June 2019 for the treatment of metastatic or recurrent NSCLC, metastatic colorectal cancer, recurrent glioblastoma multiforme, recurrent/persistent or metastatic cervical cancer, and metastatic renal cell carcinoma.
In October 2019, Denovo Biopharma, a San Diego-based biotech company, was granted the U.S. Food & Drug Administration (FDA) approval for its phase 2b clinical trial evaluating an analytical combination therapy for the treatment of newly diagnosed glioblastoma multiforme patients
In March 2018, the Australia-based Kazia Therapeutics, a biopharma company, started phase II clinical trials in the U.S. for its drug, GDC-0084. It is a novel vaccine, Rindopepimut, is in last-stage development in Australia and India for first-line GBM treatment
In December 2020, CNS Pharmaceuticals, Inc. announced that FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme
Glioblastoma Multiforme is the second most serious of all the gloom, a group of generally benign tumors growing in the cranial cavity or their central nervous system, usually in the jaw area. Generally diagnosed when symptoms are noticed, GBM usually grows slowly and over time. Clinically, glioblastomas are classified into four different grades; however, the third most serious, grade 4 or GBM, is the commonest in human beings. Like all other types of cancer, the first stage of GBM is usually the least dangerous, though it may produce symptoms that are indicative of other, more serious conditions. The third and fourth stages of GBM are considered more dangerous due to the more frequent emergence of secondary sites and the increased ability for secondary GBM to migrate.
Top Key Players Include In Recurrent Glioblastoma Multiforme Treatment Market: GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., B oehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
The Recurrent Glioblastoma Multiforme Treatment Market is displayed in 13 Chapters:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Recurrent Glioblastoma Multiforme Treatment Research Findings and Conclusion, Appendix, methodology and data source
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/682
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog
The post Recurrent Glioblastoma Multiforme Treatment Market Includes Important Growth Factor with Regional Forecast | Organization Sizes| Top Vendors appeared first on Gatorledger.
The article discusses the growth and key players in the Glioblastoma Multiforme Treatment market.
Key players include Pfizer, Denovo Biopharma, and AstraZeneca.
Increasing brain tumor incidences and new drug approvals are driving growth.
Explore more articles in the Research Reports category
